COMP <GO>
FATE vs ABBV // REVENUE GROWTH (YOY)
Fate Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: FATE 0
— ABBV 8
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $2.17 (0.00%) • MKT CAP: $260.0M
revenue-growth
-51.20%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FATE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FATE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -51.20% | 8.60% | -59.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 65.1 | -19.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $260.0M | $513.86B | -$513.60B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FATE REV | ABBV REV | FATE GROSS % | ABBV GROSS % | FATE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.6M | $61.16B | — | 70.2% | -$112.0M | $17.82B |
| FY 2024 | $13.6M | $56.33B | — | 70.0% | -$123.6M | $17.83B |
| FY 2023 | $63.5M | $54.32B | — | — | -$132.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FATE // BETA —
ABBV // BETA 1.15